<DOC>
	<DOC>NCT02158910</DOC>
	<brief_summary>The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.</brief_summary>
	<brief_title>A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients</brief_title>
	<detailed_description>This is an observational study to systematically investigate domestic patients with Alzheimer's disease to figure out the safety under a situation of the use of Donepezil HCl 23mg. Additionally, if the dose of Donepezil HCl increase, there is need to examine the safety of Donepezil HCl 23mg in depth for patients with Alzheimer's disease by comparing aspects of occurring adverse events by the type of Donepezil HCl increase.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria 1. Patients who admitted the reading and using of his/her biographical and medical data by word 2. Patients who maintained Aricept dosage for at least 3 months before involved in the study Exclusion Criteria 1. Hypersensitivity to the active substance or to any of the excipients 2. Breast feeding 3. Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer's disease</keyword>
</DOC>